Objective: To assess intralevator botulinum toxin type A (Botox) injections for refractory myofascial pelvic pain with short tight pelvic floor.
C hronic pelvic pain has been estimated to affect approximately 15% of women ages 18 to 50 with significant impact on the quality of life and health care costs. 1, 2 Myofascial pain as a cause of chronic pelvic pain with or without other pelvic floor pathology is well reported in the literature and causes significant morbidity for affected women. 1 It is defined as a regional condition of muscle pain and tightness characterized by the presence of myofascial trigger points, which are clinically focal hypersensitive taut bands within the muscles with an associated referred pain pattern on palpation. In myofascial pelvic pain, these trigger points are distributed over the levator muscles of the pelvic floor. Pain arising from these trigger points is believed to result from an excessive release of acetylcholine and other neurogenic inflammatory substances from the neuromuscular junction after chronic muscle contraction. 1 Management of the myofascial component of chronic pelvic pain is multidisciplinary, and treatment strategies previously described include use of steroids, nonsteroidal anti-inflammatory drugs, muscle relaxants, antidepressants, neuromodulators, selective serotonin reuptake inhibitors, selective norepinephrine reuptake inhibitors, pelvic floor physical therapy/exercise, and trigger point injection of various substances, including local anesthetic agents, steroids, and botulinum toxin (Botox, Allergan Inc, Irvine, CA). 3 Botox is a potent neurotoxin produced by the bacterium Clostridium botulinum. Its mechanism of action involves blocking cholinergic transmission and acetylcholine release at the neuromuscular junction. This blockade causes reversible flaccid paralysis of the innervated muscle and has been shown to decrease pain associated with hypertonic muscles. 2 There are several subtypes of Botox, with types A and B currently used in clinical practice after FDA approval in 1989 and 2000, respectively. 4 Use of Botox has been reported to decrease pain and improve function in cervical dystonia, limb spasticity after cerebrovascular accident, and headaches. Botox also has been used in treatment of urologic disorders such as detrusor sphincter dyssynergia and overactive bladder for more than a decade. 5 Although the use of Botox is reported to improve pain symptoms from muscle spasm in other parts of the body, such as head, neck, and back, there currently are few reports on the effectiveness of Botox injection to the pelvic floor muscle in the treatment of myofascial pelvic pain. 2 The increasing number of potential indications, wide variation of injected doses and injection techniques, as well as nonstandardized methods and outcome measures contribute to an incomplete understanding of the ideal candidates for Botox use in the pelvic floor. This highlights the need for more studies on the use of Botox for treatment of refractory myofascial pelvic pain in the setting of hypertonic pelvic floor. We aimed to report our experience on the use of intralevator Botox in a cohort with myofascial pelvic pain that has been refractory to other treatments.
MATERIALS AND METHODS
After we obtained institutional review board approval, we reviewed a retrospective cohort of all women who had at least one intralevator injection of Botox (100Y300 Units) at our institution from 2005 through 2010. Patients were identified using procedure code, and a query of the billing records and electronic medical record was performed. We abstracted patient demographic data such as age, body mass index, parity, race, menopausal status, sexual activity and prior gynecologic interventions, as well as the initial and posttreatment pelvic examination and patient-reported pain and improvement. For those who opted for injections in the hospital setting, we collected surgical characteristics including length of hospitalization, estimated blood loss, and concurrent procedures, such as cystoscopy and perineoplasty.
To be eligible for treatment with Botox, women needed to have objective evidence of pelvic floor hypertonicity with palpable contracted, cordlike muscle fibers, and tenderness by assessment of pelvic floor muscles on digital examination and to have been unresponsive to previous treatments, such as multiple pain medications, intensive pelvic floor physical therapy, and prior neuromodulation. Examination was performed by 1 of 5 providers at every visit. The providers consist of 2 urogynecology attending physicians and 3 urogynecology fellows. During the preinjection examination, patients were asked to verbally quantify tenderness on digital muscle palpation using a score of zero to 10, with zero being no tenderness with pelvic floor muscle palpation and 10 being the worst possible tenderness. Patients also were asked to categorize their pain as mild, moderate, or severe on palpation. At the postinjection visits, patients were asked whether they generally felt that their pain was improved, the same, or worsened and were again asked to quantify their tenderness on a scale of zero to 10 on palpation. These were obtained directly from the chart documentation in addition to the documented patient report of overall symptoms improvement. The pain score from the postinjection visits was categorized to make comparisons with the preinjection categorical pain rating. A value of zero was considered to be an absence of pain; values of 1 to 3 were categorized as mild pain, whereas values of 4 to 6 and 7 to 10 were categorized as moderate and severe pain, respectively. Pelvic organ prolapse quantification and postvoid residual were determined as part of the preinjection and postinjection examinations. Patients had the option of undergoing the procedure in the operating room with conscious sedation or in the office with oral analgesics.
The procedure was performed with the patient in the lithotomy position. One hundred to 300 units of Botox were diluted in preservative-free saline to achieve 10-units per milliliter concentration. A standard pudendal block kit with trumpet guide that allows for a depth of 1-cm needle penetration through vaginal mucosa into the muscle fibers was used for injection. The syringe is withdrawn before each injection to avoid intravascular injection. The dose ranges were chosen based on a published study of Botox treatment for intractable symptoms of neurogenic detrusor overactivity and pelvic pain syndromes 6 and consultation with each patient based on several factors, including the number of areas to be targeted, insurance coverage and the desire to minimize potential adverse effects.
Digital muscle palpation was used to locate tender and contracted points along major pelvic floor muscles that required injection. The index finger was used for palpation as the 20-gauge pudendal block needle with a trumpet guide was advanced to the target site piercing through the vaginal mucosa to the intended muscle groups. Several 1-mL (10 Units) injections per muscle group were performed. Some patients received 2 to 3 mL (20Y30 Units) injected per muscle group depending on the number of units of Botox used (100Y300 Units). Targeted muscles include the coccygeus, iliococcygeus, pubococcygeus, puborectalis, obturator, and pyriformis muscles. Injection locations were individualized to findings on physical examination and patient-reported tenderness at each site. Intravaginal pressure was applied for a few minutes as required for hemostasis.
The primary outcome was patient-reported tenderness on levator palpation and patient-reported symptom improvement. Secondary outcomes included time to and number of second injections and complications such as hematoma, estimated blood loss, de novo urinary retention (postvoid residual 9100 mL), fecal incontinence, constipation, and rectal pain.
Given the wide variation in the timing of patients returning to our clinic, the follow-up visits were stratified into 2 time periods: less than 6 weeks after injection (visit 1) and 6 weeks or longer after injection (visit 2). We compared pain and other symptoms as reported by women before the Botox injection with patient-reported pain and symptoms at visits 1 and 2.
All statistical tests were performed using SAS 9.3 (SAS Institute Inc, Cary, NC). All tests were two sided, and PG0.05 was considered statistically significant. Data are presented as median (interquartile range) or proportion. Paired data were compared with the Wilcoxon signed rank test or the McNemar test.
RESULTS
Thirty-one patients met the study eligibility criteria; 2 patients were lost to follow-up and excluded from the analysis. Participants' baseline characteristics are presented in Table 1 . The median age was 55.0 years (38.0Y62.0 years), and the median body mass index was 25.1 kg/m 2 (24.0Y30.6 kg/m 2 ). Most (86.2%) of the women were white, and 65.5% were postmenopausal. Dyspareunia was reported by all but one (92.3%) of the 13 sexually active women, and urinary urgency and urinary incontinence were common symptoms. Most women (79.3%) had no pelvic organ prolapse on examination, and all women had undergone pelvic floor physical therapy evaluation and treatment. Before the Botox injection, the median pain score reported from tenderness on digital palpation was 9.5 (8.0Y10.0). Seventeen women (58.6%) were given Botox injections in the office, and 12 women (41.4%) received injections in the operating room under conscious sedation. Concurrent cystoscopy was performed in 5 patients (16.1%) for varied indications, and one patient (3.2%) had concurrent perineoplasty to release a previous highly scarred repair. Estimated blood loss was less than 10 mL for all injections. All women went home on the same day; none required postoperative narcotics.
Of the 29 patients who returned for visit 1, most (20 patients [68.9%]) received 300 Units of Botox injection, whereas 4 patients (13.8%) and 5 patients (17.3%) had 100 and 200 Units of initial injections, respectively. All the women without an overall improvement in pelvic pain symptoms at the postinjection visit received 300 Units of Botox injection. All the patients who received 100 or 200 Units of Botox also had a decrease in pain score from tenderness with levator muscle palpation at this follow-up visit. Patient-reported pain score at the time of levator palpation at this visit was missing in the medical record of 2 women (6.9%); one of these women reported that, in general, her pain was improved, and the other one reported no change. Therefore, among all the 29 women, 23 women (79.3%) reported some improvement in pain symptoms, whereas 6 women (20.7%) reported no improvement; there were no reports of worsened pain after the Botox injection.
For the 26 women with a documented pain score before and after the Botox injection, the median pain score with levator tenderness on palpation at visit 1 was significantly lower than the preinjection pain score (PG0.0001). Before the injection, all the 29 women reported either moderate (10.3%) or severe (89.7%) pain from levator tenderness on palpation. At visit 1, more than half of the women (51.7%) reported no pain on digital palpation of previously tender trigger points on the levator muscles and 6 patients (20.7%) had mild pain. Two patients (6.9%), both of whom previously reported severe pain, had moderate pain at visit 1, whereas 4 patients (13.8%) continued to have severe pain upon digital palpation of the tender levator muscles. Two of these 4 patients with persistent severe pain received Botox injection in the operating room, whereas the other 2 patients had their Botox injection in the office. Of the 2 women for whom a pain score was missing at visit 1, one reported moderate pain before the Botox injection and one previously reported severe pain. The prevalence of self-reported urinary incontinence reported decreased significantly from 41.4% before the injection to 13.8% at visit 1 (P=0.008; Table 2 ).
Eighteen women (62.1%) returned for visit 2 and had a median pain score of 3.0 (0.0Y6.0), which remained lower than the preinjection rating (PG0.0001). Of these women, 66.7% reported overall improvement in pain symptoms. Whereas 7 patients (38.9%) had no pain upon digital palpation of previously tender levator trigger points, 4 patients (22.2%) had mild pain, 3 patients (16.7%) had moderate pain, and 4 patients (22.2%) had severe pain. The prevalence of self-reported urinary incontinence was lower at visit 2 than before the Botox injection (P=0.03; Table 2 ).
Fifteen (51.7%) of the 29 women in our cohort elected to have a second Botox injection, with a median of 1.0 second injection (1.0Y2.0 second injections). The median time from the initial to second treatment was 4.0 months (3.0Y7.0 months). Two of the patients that reported no improvement at visits 1 and 2 opted to have a second injection at 3 months and 7 months after the initial injection. The remaining 13 women that elected to undergo a second Botox injection initially reported improvement in pain after the injection with a range of 2 to 30 months between their initial injection and the second injection.
Compared to baseline, the median postvoid residual was higher at visits 1 and 2, but the differences were not statistically significant (both P90.05). A total of 4 patients met criteria for urinary retention with PVR9100 mL after Botox injection. All 4 patients received 300 Units of Botox injection. One of the 4 patients had urinary retention requiring intermittent selfcatheterization that preceded the Botox injection. Three of the women with de novo urinary retention required intermittent selfcatheterization with PVR volumes ranging from 150 to 550 mL; their urinary retention subsequently resolved at the 12-week postinjection office visit. Two women (6.9%) reported fecal incontinence at visit 1 with complete resolution at 7 and 20 weeks. Both women also received 300 Units of Botox injection each. Three women (10.3%) reported significant constipation and/or rectal pain after injections. These symptoms resolved by visit 2. There were no serious adverse events reported (Table 3) .
DISCUSSION
Botox has been used to treat a variety of pain conditions, including focal dystonia, spasticity, myofascial pain syndrome, and headaches. 6 Our objective was to evaluate the use of Botox for myofascial pelvic pain that had been refractory to other treatments. Our findings suggest that intralevator injection of Botox is at least moderately effective in women with refractory myofascial pelvic pain as evidenced by a significant decrease in patient-reported pain after Botox injection for most of the women in our study. More than half of the patients in our study elected to have a second Botox injection as a result of the improvement they experienced with previous injections.
Our findings are consistent with a randomized placebocontrolled study evaluating the efficacy of Botox injection to the pelvic floor muscle in patients with chronic pelvic pain and with evidence of pelvic floor muscle spasm. This study reported a reduction in resting tension and pelvic floor muscle pressure that translated to a reduction in nonmenstrual pelvic pain and dyspareunia in patients injected with Botox compared to the placebo group. 7 Other studies also have reported significant improvement in patient-reported pain, quality of life, and oral pain medication use for 8 to 14 weeks after Botox injections in patients with vaginismus and vestibulodynia. 8Y9 Although the etiology of chronic pelvic pain is not well understood and is usually multifactorial, the management of the myofascial component can be advantageous for women with chronic pelvic pain. Jarvis et al showed evidence that Botox injection into the pelvic floor muscles resulted in a 37% reduction in resting pressure at 4 weeks and a 25% reduction maintained at 12 weeks after Botox injection; the resulting pelvic floor relaxation was reported as a factor for reducing pain sensation. 2 This same mechanical effect of Botox-induced muscle relaxation was seen in women with outlet obstruction due to failure of relaxation or to paradoxical contraction of the puborectalis muscle. Constipation and anismus improved in up to 50% of patients with long-term treatment success. 10 There also is evidence suggesting that treatment directed at the pelvic 11, 12 Our study further supports the use of intralevator injection of Botox as a treatment option for women with refractory myofascial pelvic pain. The use of Botox injection to the pelvic floor in our patient population resulted in only minimal and reversible adverse effects, such as transient de novo urinary retention, fecal incontinence, constipation, and rectal pain, all of which resolved spontaneously. There were no serious long-term nonreversible adverse events reported in our study. After injection directly into the palpated trigger points of the pelvic floor muscles, the patients with refractory myofascial pelvic pain symptoms had significant reduction in their pain severity both by report and on pain scale during physical examination by digital palpation. We also found a decrease in patient-reported urinary incontinence at both postinjection visits. Although the direct effect of Botox injection to the pelvic floor on bladder function has not been studied, its use in refractory overactive bladder via injection to the bladder detrusor has been shown to be efficacious. Although we cannot specify the mechanism by which Botox may improve urinary incontinence symptoms, this finding may be the result of pelvic floor relaxation and decrease in pain that can affect an irritative voiding pattern. Similarly, although it is not fully understood why injection into the levator muscle will elicit adverse effect of urinary retention, we observed that all the patients with urinary retention after the injection all received a higher dose (300 Units) of Botox. We can also hypothesize the potential of spread after the injection of Botox into adjacent tissue including bladder detrusor, which may contribute to the resulting findings of urinary retention, although more studies will be needed to establish this as a potential mechanism for the urinary retention.
Our study describes one clinic's experience with intralevator Botox injection to treat a condition for which there is limited published research and has several limitations, including its relatively small sample size and retrospective design. Owing to the retrospective design, the dosing and injection sites were not standardized; there was inconsistency in the timing of follow-up visits, and pain data was missing for 2 women. In addition, we were unable to standardize the palpation technique for the myofascial trigger points. Although physicians made an effort to be consistent in the pressure applied during the examination, the amount of pressure could have influenced patient-reported pain. We did not use a scoring system for diagnosing hypertonicity as other studies have done with the use of muscle manometry. Our general clinical approach to objective assessment of the pelvic floor muscles involves palpation for muscle attenuation or thinning as well as palpation for muscle fibers contraction and tight cordlike bands. In this retrospective study, although we did not have a scoring system for hypertonicity, it will be a consideration for future prospectively designed study with measurable effect of Botox on actual muscle tonicity. Given referral patterns to our practice, it also is likely that this population of women had more advanced pathology, as evidenced by the fact that they all had prior evaluation and treatment, including pelvic floor physical therapy.
There does not seem to be a direct dose response correlation of the dose of Botox used and the pain improvement in our retrospective review. Most of the patients received 300 Units of Botox injection. Most of the patients who received the highest Botox dose (300 Units) reported improvement in postinjection tenderness to digital palpation, which was also evident in all the patients who received 100 and 200 Units. All the women without an overall improvement in pelvic pain symptoms and tenderness to digital palpation at the postinjection visit received 300 Units of Botox injection.
Our general practice approach to Botox injection is to offer the option of injection in the office or the operating room. Patients generally decide on their preference and are generally based on their ability to tolerate office pelvic examination. Other factors that are considered include the need for concomitant procedures that are not office-based procedures. In our retrospective review, we found that equal numbers of patients in the office injection group and the operating room group continued to report severe pain at their post-Botox injection follow-up visit. When patients are able to tolerate the injections in the office, the same approach to injection is used and the same muscle groups are targeted.
In conclusion, our results demonstrate a significant decrease in patient-reported pain after Botox injection to the pelvic floor in our population with chronic myofascial pelvic pain. As this condition has both physical and psychological components, care of these women requires a multidisciplinary approach to both diagnosis and management. In patients who have failed conservative treatment approaches, the use of intralevator Botox injection may be an effective option with minimal to no long-term adverse effects. Randomized trials using placebo comparisons are needed to fully assess the effectiveness of Botox for the treatment of chronic myofascial pelvic pain and to evaluate long-term outcomes, treatment adverse effects, and potential long-term risks.
